Search for content, post, videos

Scandion Oncology receives DKK 5 million

Nils Brunner
Scandion Oncology A/S has obtained DKK 5 million from Innovation Fund Denmark for the clinical development of SCO-101 in metastatic pancreatic cancer. The grant of DKK 5 million from Innovation Fund Denmark is earmarked for the clinical phase II development of SCO-101 in metastatic pancreatic can
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.